This provides a reference for future development of FNIP1-targeted drug therapies for mitochondrial diseases and improving patients prognosis with reduced stress, inflammatory response, skeletal muscle damage, et. This evidence concerns the gene FNIP1 and inborn mitochondrial metabolism disorder.